



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/744,799	04/03/2001	Paulus Jacobus Antonius Sondermeijer	I/98404 US	4801

31846 7590 07/15/2005

INTERVET U.S.  
PATENT DEPARTMENT  
PO BOX 318  
MILLSBORO, DE 19966-0318

EXAMINER

SALIMI, ALI REZA

ART UNIT PAPER NUMBER

1648

DATE MAILED: 07/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b> 09/744,799	<b>Applicant(s)</b> SONDERMEIJER ET AL.	
	<b>Examiner</b> A R. Salimi	<b>Art Unit</b> 1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 27 January 2005.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 16-43 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 16-43 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 30 January 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>1/30/01</u> . | 6) <input checked="" type="checkbox"/> Other: <u>Sequence Requirements</u> .            |

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Attenuated and mutated sequences should be filed. otherwise,  
No reasonable search can be performed,

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

### **DETAILED ACTION**

Please note the application has been transferred to a new examiner, as Examiner Laurie Scheiner is no longer with the Office. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to examiner Salimi.

#### ***Response to Amendment***

This is a response to the amendment filed 5/28/04. Claims 16-43 are pending before the examiner.

#### ***Election/Restrictions***

Previously sent written restriction mailed 5/4/04 is now vacated. Examination of the claims is not undue burden. Claims are rejoined. Claims 16-43 will be considered.

#### ***Sequence Requirements***

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent

Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

This application is claiming isolated nucleic acid sequences and its mutant variations. However, the application fails to comply with the sequence requirements. For the most part the claimed invention is directed to products, and no sequence identification has been submitted that identifies the products. The sequences are required elements for a through search to be performed to ensure no earlier application has interfering subject matter with now claimed

Art Unit: 1648

products (emphasis added). What Applicants have submitted is not sufficient compliance with 37 CFR 1.821 through 1.825.

Full compliance with the sequence rules is required in response to this Office Action. A complete response to this office action should include both compliance with the sequence rules and a response to the Office Action requirement set forth below. Failure to fully comply with **both** these requirements in the time period set forth in this office action will be held non-responsive.

***Claim Rejections - 35 USC § 112***

Claims 16-28, 32-43 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 16, 22, 24, 32, and 43 are vague, and indefinite, the intended metes and bounds of the EHV mutant(s) is/are not defined. The claims have been interpreted in light of the specification and since it is not clear where the mutant sequences begin and where they end it is very difficult to determine the boundaries of claimed invention. Moreover, no practical search can be conducted where the boundaries are uncertain. Identifying the claims by a specific sequence identification number would obviate this rejection. This affects the dependent claims.

Claim 28 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential elements, such omission amounting to a gap between the elements. See MPEP § 2172.01. The omitted elements are: the intended DNA molecule is missing, and the specification does not provide adequate teaching for the said molecule.

Art Unit: 1648

Claims 16-20 are objected to for being substantial duplicates of claims 32-36. The difference in the claimed products is not apparent. Please clarify the difference.

***Claim Rejections - 35 USC § 101***

35 U.S.C. §101 states:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claim 25 is rejected under 35 USC 101 because the claimed invention is directed to non-statutory subject matter.

Claim 25, as written, do not sufficiently distinguish over cells a as they exist naturally because the claim does not particularly point out any non-naturally occurring differences between the claimed products and the naturally occurring products. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. *See Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, e.g., by insertion of "Isolated." See MPEP 2105.

***Claim Rejections - 35 USC § 112***

Claims 16-43 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of forming an attenuated EHV-1 by deleting a 160 bp of IE promoter to be used as a vaccine wherein the deletion would reduce the level of expression of IE gene in addition to the product as defined by EHV23 (assuming the plasmid can meet the deposit

Art Unit: 1648

requirement under Budapest Treaty), does not reasonably provide enablement for a general EHV mutant comprising one or more deletions, substitutions or insertions introduced into the endogenous promoter region, or an isolated nucleic acid molecule deletion in IE gene. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. The disclosure is extremely deficient in providing an adequate teaching for one of ordinary skill in the art to enable claimed invention. This field is highly unpredictable, as Applicants' own disclosure has stated as such. The specification has a general statement regarding mutating a well known sequence of EHV-1, and subjecting the promoter region to large deletions, insertions, or mutations which would not disable the virus but reduces the expression of IE. However, the level of teaching provided is not compatible with patent protection requested. Each mutation, deletion, insertion is different and presumably would have different effect on interaction, antigenicity and virulence of the virus. The effect of the mutations, insertions, or deletions, is unpredictable and the said modifications at one location do not teach or suggests effects at a different location. For instance, the disclosure asserts that a stable mutation needs to be introduced at both positions simultaneously before the new phenotype can be expressed. The claims do not, however, reflect this teaching. The claims are directed to a general insertion, deletion, or mutations. This has to be reconciled. A general mutation, insertion, or deletion may not do anything to the virus infectivity or may disable the virus, or may make it more infectious. Applicants' own disclosure shows that efficacy was achieved when a large portion of IE promoter was deleted in the form of EHV23, and nothing more. To practice the full scope of the claimed invention one of ordinary skill in the art would be required to conduct large quantity of

Art Unit: 1648

undue experimentation. Moreover, Applicants have only shown positive results when EHV23 was administered, however, the scope of the claims are directed to vaccines for all EHV mutants. However with regard to an unpredictable field, this does not constitute an adequate disclosure. See *Fiers v. Revel* (25USPQ2d 1601 at 1606; and also decision by the Federal Circuit with regard to the enablement issues see *Genentech Inc. v. Novo Nordisk A/S*, 42 USPQ2d 1001-1007). For example, the CAFC stated that "It is the specification, not the knowledge of one skilled in the art that must supply the novel aspects of an invention in order to constitute enablement." (See page 1005 of the decision). In the instant case the specification does not teach or provide any guidance for development of a general vaccine. This means that the disclosure must adequately guide the art worker to determine, without undue experimentation. Applicants cannot rely on the knowledge of those skilled in the art to enable the claims without providing adequate teaching. Therefore, considering large quantity of experimentation needed, the unpredictability of the field, the state of the art, and breadth of the claims, it is concluded that undue experimentation would be required to enable the intended claim. Many of these factors have been summarized *In re Wands*, 858 F.2d 731, USPQ2d 1400 (Fed. Cir. 1988).

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a **written description** of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 16-43 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had



Art Unit: 1648

**possession** of the claimed invention. In the instant disclosure Applicants have only disclosed a method of manipulation of IE promoter region of EHV-1 wherein 160 nucleic acids were deleted and formation of one viable plasmid, i.e. EHV23. No other sequences of EHV which comprise a general mutations, substitution or insertion, or attenuated virus were disclosed. No host cells are disclosed. No recombinant molecule that comprises EHV is disclosed. No attenuated EHV mutant is disclosed, or a mutant virus. The specification does not set forth the metes and bounds of what encompasses in the claims, and there is not enough information about it in literature either to guide the one of ordinary skill in the art to predict the undisclosed regions. In addition, if the Applicants did not possess the products, then they were not in possession of the method either, because in order to practice the broad method one needs the product. Therefore, a written description of the other claimed sequences is lacking. See also *University of California v. Eli Lilly and Co.*, 43 USPQ2d 1398 (Fed. Cir. 1997), which teaches that the disclosure of a process for obtaining cDNA from a particular organism and the description of the encoded protein fail to provide an adequate written description of the actual cDNA from that organism which would encode the protein from that organism, despite the disclosure of a cDNA encoding that protein from another organism. 35 USC 112 requires inter alia that a patent specification contain a written description of the invention and the manner and process of making and using it "in such full clear and concise terms as to enable one skilled in the art ... to make and use" the invention. Case law has made it clear that the requirements for a "written description" and an "enabling disclosure" are separate. For example, where a specification contains sufficient information to enable a skilled chemist to produce a particular compound because it gives detailed information on how to produce analogous compounds but it makes no reference to the compound in question,

Art Unit: 1648

the "written description" requirement has not been met even though the description may be enabling.

See *University of California v. Eli Lilly*, 19 F.3d 1559, 43 USPQ 2d 1398 (Fed. Cir. 1997):

The name cDNA is not in itself a written description of that DNA; it conveys no distinguishing information concerning its identity. While the example provides a process for obtaining human insulin-encoding cDNA, there is no further information in the patent pertaining to that cDNA's relevant structural or physical characteristics; in other words, it thus does not describe human insulin cDNA .... Accordingly, the specification does not provide a written description of the invention ....

and at pg 1406:

a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA," without more, is not an adequate written description of the genus because it does not distinguish the genus from others, except by function. It does not specifically define any of the genes that fall within its definition. It does not define any structural features commonly possessed by members of the genus that distinguish them from others. One skilled in the art therefore cannot, as one can do with a fully described genus, visualize or recognize the identity of the members of the genus. A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the genes does, not what it is.

See *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ 2d 1016 at page 1021:

A gene is a chemical compound, albeit a complex one, and ... conception of a chemical compound requires that the inventor be able to define it so as to distinguish it from other materials .... Conception does not occur unless one has a mental picture of the structure of the chemical or is able to define it by its method of preparation, its physical or chemical properties, or whatever characteristics sufficiently distinguish it. It is not sufficient to define it solely by its principal biological property, e.g., encoding human erythropoietin, because an alleged conception having no more specificity than that is simply a wish to know the identity of any material with that biological property.

No claims are allowed.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to A. R. Salimi whose telephone number is (571) 272-0909. The examiner can normally be reached on Monday-Friday from 9:00 Am to 6:00 Pm.

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (571) 272-0902. The Official fax number is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

A. R. Salimi

7/13/2005

ALL R. SALIMI  
PRIMARY EXAMINER